Fred Grossman

Company: Coya Therapeutics

Job title: President & Chief Medical Officer

Seminars:

Coya 302: A Dual Mechanism Biologic Immunotherapy in the Treatment of ALS By Treg Activity to Reduce Inflammation 1:10 pm

Treg dysfunction is a core driver of neurodegeneration in ALS Coya 302 immunotherapy targets adaptive and innate immune pathways in ALS with strong efficacy signal in an open label exposure trial Advancing Coya 302 in a double-blind placebo controlled clinical trial in ALSRead more

day: Day Two Track B PM

Navigating the Hurdles of a Combination Therapy Approach & the Need to Demonstrate Efficacy on Top of Existing ALS Treatments 11:05 am

In a world where numerous ALS drugs begin to exist, new challenges of trial enrolment, patient availability and an evolving standard of care emerge. Engage in forward-thinking discussions around the future of ALS drug development as increasing numbers of therapies reach the clinic: How can we overcome anticipated trial complications due to varying standards of…Read more

day: Pre-Conference Day